cbdMD, Inc. (YCBD)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 42 | 44 | 35 | 24 | 19 | 19 | 21 | 22 |
| Operating profit | $m | -2 | -3 | ||||||
| Net profit | $m | 13 | -23 | -70 | -23 | -4 | -2 | -3 | -1 |
| EPS reported | $ | -1.09 | -0.31 | ||||||
| Operating cashflow per share | $ | -0.36 | -0.24 | ||||||
| Capex per share | $ | 0.05 | 15.78 | ||||||
| FCF per share | $ | -0.41 | -15.94 | ||||||
| Free cash flow | $m | -2 | -626 | ||||||
| Net debt | $m | 775 | -2 | ||||||
| Book value equity | $m | 7 | 8 | ||||||
| Book value per share | $ | 1.80 | 0.77 | ||||||
| Number of shares | m | 4.02 | 10.62 | ||||||
| DPS (TTM paid) | $ | 0.00 | 11.33 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | - | ||||||
| P/B LTM | x | 0.67 | 0.59 | ||||||
| P/S LTM | x | 0.25 | 0.23 | ||||||
| P/FCF LTM | x | -2.97 | -0.01 | ||||||
| EV/EBITDA LTM | x | -3,187.39 | -482.11 | ||||||
| EV/Sales LTM | x | 40.69 | 0.18 | ||||||
| Earnings Yield LTM | % | -41.93% | -45.40% | ||||||
| FCF Yield | % | -33.62% | -12861.1% | ||||||
| Quality | |||||||||
| ROE | % | -28.24% | -33.59% | ||||||
| ROIC | % | -0.28% | -27.60% | ||||||
| Operating margin | % | -11.27% | -13.40% | ||||||
| Gross margin | % | +62.37% | +58.12% | ||||||
| FCF/Sales | % | -8.53% | -833.04% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | -1.50% | +7.44% | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | -0.00 | -282.97 | ||||||
| Net Debt/EBITDA | x | -3,167.52 | 2.38 | ||||||
| EBIT/Net interest | x | 0.00 | 0.00 | ||||||
| Net debt/market cap | % | +159.89% | +0.12% | ||||||
| Net debt/Equity | x | 107.28 | -0.26 | ||||||
| Gross debt/equity | x | 107.70 | 0.27 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
cbdMD, Inc. is engaged in the production and distribution of a diverse array of cannabidiol (CBD) products. The company oversees and markets several consumer-oriented, hemp-derived CBD brands, notably its primary brand cbdMD, alongside Paw CBD and cbdMD Botanicals. Under the cbdMD label, its offerings span various items, including CBD tinctures, edible gummies, topical applications, capsules, bath bombs, bath salts, and solutions designed to aid sleep. Furthermore, its Paw CBD brand caters to pets with veterinarian-formulated products such as tinctures, edible chews, and topical treatments. The company's merchandise reaches customers throughout the United States via its proprietary e-commerce platform, various third-party online retail sites, wholesale partners, and physical brick-and-mortar establishments. cbdMD, Inc. also maintains a research collaboration with the University of Mississippi, focusing on the discovery of novel cannabinoids. Incorporated in 2015, the firm was previously known as Level Brands, Inc. before officially changing its name to cbdMD, Inc. in May 2019, and its corporate headquarters are situated in Charlotte, North Carolina.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
cbdMD, Inc. is engaged in the production and distribution of a diverse array of cannabidiol (CBD) products. The company oversees and markets several consumer-oriented, hemp-derived CBD brands, notably its primary brand cbdMD, alongside Paw CBD and cbdMD Botanicals. Under the cbdMD label, its offerings span various items, including CBD tinctures, edible gummies, topical applications, capsules, bath bombs, bath salts, and solutions designed to aid sleep. Furthermore, its Paw CBD brand caters to pets with veterinarian-formulated products such as tinctures, edible chews, and topical treatments. The company's merchandise reaches customers throughout the United States via its proprietary e-commerce platform, various third-party online retail sites, wholesale partners, and physical brick-and-mortar establishments. cbdMD, Inc. also maintains a research collaboration with the University of Mississippi, focusing on the discovery of novel cannabinoids. Incorporated in 2015, the firm was previously known as Level Brands, Inc. before officially changing its name to cbdMD, Inc. in May 2019, and its corporate headquarters are situated in Charlotte, North Carolina.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free